Evaluating the Effect of Anagrelide on Fibroblast Growth Factor-2 Levels

Science Press Release Distribution Services

Evaluating the Effect of Anagrelide on Fibroblast Growth Factor-2 Levels

August 3, 2022 Medical Science 0

The purpose of this study is to examine how ANA affects platelet endothelial activation and FGF-2 release. Myelofibrosis is one of the normal outcomes of essential thrombocythemia. The myelosuppressive medicine used by ET itself may increase the risk of myelofibrosis development. A major challenge in treating ET is minimizing this risk. It is believed that fibroblast growth factor-2 is released by activated thrombocythemic platelets (FGF-2). The myelosuppressive drug anagrelide (ANA) inhibits platelet activity. The main worry with ANA is that it can raise the potential risk of developing myelofibrosis. In this study, we provide the outcomes of a randomized group of ET patients receiving ANA therapy who, after a 5-year follow-up, demonstrated a decrease in myelofibrosis. The fact that ANA has a wider action that also impacts platelet function is a likely reason for this finding. In the current study, we found that ANA normalizes FGF-2 levels by preventing platelet endothelial activation, which improves the myeloproliferation and fibrosis outcomes for ET patients.

Author(s) Details:

Rossella Cacciola,
Department of Clinical and Experimental Medicine, Haemostasis Unit, University of Catania, Italy.

Elio Gentilini Cacciola,
Department of Clinical and Experimental Medicine, Haemostasis Unit, University of Catania, Italy.

Emma Cacciola,
Department of Medical, Surgical and Advanced Technologies Sciences “G.F. Ingrassia”, Unit of Haemostasis, University of Catania, Italy.

Please see the link here: https://stm.bookpi.org/CPMS-V5/article/view/7661

Keywords: Essential thrombocythemia, platelet activation, FGF-2, myelofibrosis, anagrelide

 

Leave a Reply

Your email address will not be published.